Armata Pharmaceuticals (ARMP) vs Cellectis S.A. (CLLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Armata Pharmaceuticals (ARMP) has outperformed Cellectis S.A. (CLLS) over the past year, gaining 19.9% versus a loss of 64.9%. Over five years, ARMP leads with a +10.4% price change compared with -87.6% for CLLS. Armata Pharmaceuticals is the larger company by market cap ($143.5 million vs $125.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARMP | CLLS |
|---|---|---|
| Share price | $3.86 | $1.25 |
| Market cap | $143.52M | $125.90M |
| 1-day change | +1.31% | -6.72% |
| YTD return | -38.54% | -72.31% |
| 1-year return | +19.88% | -64.92% |
| 5-year return | +10.43% | -87.63% |
| EPS (TTM) | $-5.29 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.34 | $5.48 |
| 52-week low | $3.09 | $1.22 |
| Distance from 52-week high | -76.38% | -77.19% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +353.37% | +326.40% |
| Average volume | 210.93K | 78.59K |
| Shares outstanding | 37.18M | 72.72M |
| Employees | 61 | 224 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARMP has outperformed CLLS by 84.8 percentage points over the past year.
About Armata Pharmaceuticals
ARMP stock →Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 61 employees
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
ARMP vs CLLS FAQ
Which is bigger, Armata Pharmaceuticals or Cellectis S.A.?
Armata Pharmaceuticals (ARMP) is larger, with a market capitalization of $143.52M compared with $125.90M for Cellectis S.A. (CLLS).
Which stock has performed better over the past year, ARMP or CLLS?
ARMP returned +19.88% over the past 12 months, compared with -64.92% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Armata Pharmaceuticals and Cellectis S.A. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Armata Pharmaceuticals and Biotechnology: Pharmaceutical Preparations for Cellectis S.A..